Lilly’s Orforglipron Demonstrates Clear Superiority Over Semaglutide in Reducing A1C and Weight
Lilly announced topline results from its ACHIEVE-3 Phase 3 trial, and the numbers are hard to ignore: orforglipron, Lilly’s oral GLP-1 candidate, outperformed oral semaglutide across every efficacy measure for adults with type 2 diabetes. This randomized trial, which enrolled 1,698 participants, set out to directly compare the two leading oral options for those with diabetes inadequately controlled on metformin.
After 52 weeks, patients on orforglipron not only lowered their average blood sugar (A1C) more, but also lost significantly more weight—up to a 73.6% relative improvement in weight loss compared to semaglutide at the highest tested doses.
Key Efficacy Data: A1C and Weight Loss Improvements Set New Benchmarks
| Measure | Orforglipron 12 mg | Orforglipron 36 mg | Semaglutide 7 mg | Semaglutide 14 mg |
|---|---|---|---|---|
| Change in A1C (%) | -1.90 | -2.20 | -1.10 | -1.40 |
| Change in Weight (%) | -6.70 | -9.20 | -3.70 | -5.30 |
| Avg. Weight Loss (lbs) | -14.60 | -19.70 | -7.90 | -11.00 |
| % Achieving A1C <5.7% | 25.40 | 37.10 | 7.80 | 12.50 |
Notably, the highest orforglipron dose (36 mg) resulted in a 2.2% reduction in A1C, a 9.2% body weight reduction, and 37.1% of participants achieving near-normal blood sugar levels. These outperformed the results seen with both semaglutide doses.
Safety Profile Consistent with Earlier Trials, Tolerability Acceptable
Orforglipron’s safety and tolerability was in line with previous trials. The most common side effects were mild-to-moderate gastrointestinal events. Treatment discontinuations due to adverse events were 8.7% for the 12 mg dose and 9.7% for 36 mg, compared to 4.5% and 4.9% for semaglutide 7 mg and 14 mg, respectively. No concerning liver signals were seen for orforglipron.
Orforglipron’s Potential: More Than Just Another GLP-1
With its superior efficacy, oral once-daily dosing, and ability to be taken with or without food, orforglipron could reshape the landscape for type 2 diabetes and weight management—especially as oral therapies grow in demand. Beyond glycemic control and weight loss, orforglipron also delivered meaningful improvements in key cardiovascular risk factors such as non-HDL cholesterol, systolic blood pressure, and triglycerides, supporting its broader health impact.
The ACHIEVE Phase 3 program continues globally, and Lilly expects to submit orforglipron for regulatory approval in 2026. Full trial details will be shared at future medical meetings and through peer-reviewed publication.
What This Means for Diabetes Care and Investors
Lilly’s press release highlights not just an incremental step forward, but a clear leap over existing oral GLP-1 therapies in efficacy and versatility. As regulatory submission draws closer, orforglipron’s trial performance raises new questions about how quickly this candidate could become foundational in diabetes treatment. Investors and healthcare professionals will be watching for detailed data, long-term outcomes, and broader adoption in future studies.
For those following innovation in diabetes, orforglipron just set a high bar for the next generation of oral treatments.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI